which comes either as an auto-injector or as a pre-filled syringe. Indications for which Humira’s regulatory exclusivity have already lapsed include rheumatoid arthritis, Crohn’s disease ...

Yesterday, Amgen announced that it would launch the U.S.’s first marketed Humira-referenced biosimilar, Amjevita (adalimumab-atto), at two different list prices: $3,288 and $1,557 per 40 mg pen ...